Warning:
Be aware of fake ESCMID Global websites and fraudulent emails. Only use the official ESCMID Global online registration for your bookings.
Search
Frequent searches
Suggestions

ESCMID Global 2026 Categories and Subcategories

  • 1a. HIV/AIDS (incl diagnostics & epidemiology, anti-retroviral drugs, vaccines, treatment & susceptibility/resistance)
  • 1b. Viral hepatitis (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance)
  • 1c. Influenza and respiratory viruses (incl diagnostics & epidemiology, antiviral drugs, vaccines, treatment & susceptibility/resistance) 
  • 1d. Herpesviruses (incl diagnostics & epidemiology, antiviral drugs, treatment & susceptibility/resistance, excl clinical studies in immunocompromised hosts)
  • 1e. Emerging/re-emerging, vector-borne and zoonotic viral diseases (other than COVID)
  • 1f. Diagnostic virology (other than respiratory viruses, herpesviruses, hepatitis & HIV; incl traditional, molecular, genomic and other methods)
  • 1g. Viral epidemiology – general, prevalence studies, molecular and genomic epidemiology (other than respiratory viruses, herpesviruses, hepatitis & HIV)
  • 1h. Antiviral drugs, treatment, susceptibility/resistance (other than respiratory viruses, herpesviruses, hepatitis & HIV)
  • 1i. Fundamental and applied virology (incl in vitro and in vivo models, novel methods)
  • 1j. COVID-19 (incl virology, epidemiology, evolution, immune response, diagnosis, treatment, vaccination, prevention, response and societal impact)
  • 2a. Tuberculosis and other mycobacterial infections (incl epidemiology, clinical, diagnostics, antimycobacterial drugs, susceptibility testing, treatment & prevention)
  • 2b. Severe sepsis, bacteraemia & endocarditis (incl epidemiology, diagnosis, host biomarkers, treatment, and outcome prediction)
  • 2c. Community-acquired respiratory infections (incl epidemiology, clinical features, imaging, treatment & prevention)
  • 2d. Community-acquired abdominal/gastrointestinal infections (incl epidemiology, clinical, imaging, treatment & prevention)
  • 2e. Community-acquired urinary tract & genital tract infections (incl epidemiology, clinical, imaging, treatment & prevention)
  • 2f. Community-acquired skin, soft tissue, bone & joint infections (incl epidemiology, clinical, imaging, treatment & prevention, excl prostheses) 
  • 2g. Community-acquired nervous system and other multi-system or invasive bacterial infections (incl epidemiology, clinical, imaging, treatment & prevention)
  • 2h. Zoonotic bacterial infections (incl vector-borne pathogens, excl AMR)
  • 2i. Other intracellular or rare bacteria
  • 3a. Resistance surveillance & epidemiology: Community-acquired bacteria
  • 3b. Resistance surveillance & epidemiology: Healthcare-associated bacteria
  • 3c. Susceptibility testing methods (incl assay validation, phenotypic assays and comparative studies, excl TB)
  • 3d. Resistance mechanisms (incl in vitro and in vivo studies, mobile elements, excl TB)
  • 3e. Resistance detection/prediction approaches (rapid and/or molecular assays, resistome analysis, inference methods)
  • 3f. Clinical outcome of resistant infections (retrospective and prospective studies, excl clinical trials of new drugs, excl case series)
  • 3g. Spread of resistance (incl carriage, reservoirs, ecology, One Health models, excl nosocomial transmission)
  • 3h. Policy aspects of AMR (incl societal impact, economics, mitigation)
  • 4a. Diagnostic bacteriology (incl culture based, traditional and general microbiology, serology, excl AST methods)
  • 4b. Laboratory management (incl automation, data management, QC/QA, regulatory aspects)
  • 4c. MALDI-TOF and other proteomic methods
  • 4d. Molecular diagnostics (incl POCT and syndromic testing)
  • 4e. Strain typing and surveillance (incl molecular, genomic and other advanced methods)
  • 4f. Whole genome sequencing (incl pathogen characterisation, diagnostics, excl typing) 
  • 4g. Microbiome studies (incl clinical and diagnostic studies, One Health aspects, excl fundamental science)
  • 4h. Clinical metagenomics
  • 4i. Bioinformatics tools & pipelines
  • 4j. Artificial intelligence based tools and digital health
  • 4k. Other novel diagnostic technologies 
  • 5a. Drug discovery and new compounds mechanisms of action & spectrum, preclinical data & basic pharmacology (incl drug design, investigational and non-traditional therapeutics)
  • 5b. Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring (incl lab methods, models, in vitro and in vivo studies)
  • 5c. New or repurposed antibacterial agents: Clinical studies and randomised trials
  • 5d. Antimicrobial stewardship and prescribing (incl interventions, monitoring, impact, decision-support/prediction tools, behavioural aspects)
  • 5e. Safety, hypersensitivity and adverse effects of treatment
  • 5f. Pharmacoepidemiology/pharmacoeconomics (incl cost-effectiveness, modelling, data tools) 
  • 6a. Fundamental mycology (incl in vitro and in vivo studies, pathogenesis, virulence, mycobiome)
  • 6b. Fungal disease epidemiology 
  • 6c. Diagnostic mycology (incl traditional, molecular and other methods)
  • 6d. Antifungal susceptibility testing & resistance (incl surveillance, mechanisms)
  • 6e. Antifungal drugs & treatment (incl pre-clinical studies and clinical trials) 
  • 7a. Fundamental parasitology
  • 7b. Parasitic disease epidemiology
  • 7c. Diagnostic parasitology (incl traditional, molecular and genomic methods)
  • 7d. Antiparasitic drugs & treatment (incl pre-clinical studies and clinical trials)
  • 7e. Antiparasitic susceptibility & drug resistance (incl surveillance, mechanism)
  • 7f. Travel medicine, migrant and refugee health 
  • 8a. Intravascular catheter-related infections (incl epidemiology, prevention)
  • 8b. Other foreign-body and implant-associated infections (incl PJI)
  • 8c. Surgical site infections
  • 8d. Healthcare-associated pneumonia (incl VAP)
  • 8e. Hospital epidemiology, transmission, surveillance & screening (incl. hospital environment) 
  • 8f. Other healthcare associated infections (incl CDI, hospital outbreaks)
  • 8g. Infection control interventions and trials (incl microbiota transplantation)
  • 8h. Disinfection & sterilisation (incl medical device reprocessing)
  • 8i. Healthcare workers and infection prevention (incl vaccination, protective equipment, behavioural aspects, training and practices) 
  • 9a. Microbial pathogenesis & virulence
  • 9b. Host-pathogen interaction (incl basic microbiome studies, animal models)
  • 9c. Pre-clinical biofilm studies
  • 9d. Experimental and cellular microbiology 
  • 9e. Fundamental science studies using Omics (in vitro and in vivo)
  • 9f. Immune response to infection (incl in vitro, animal and human studies, laboratory assessment of immunity and response, excl sepsis biomarkers) 
  • 10a. Host genetics: Susceptibility to infection & primary immunodeficiency
  • 10b. Infections related to solid organ transplantation
  • 10c. Infections related to haematopoietic stem cell transplantation
  • 10d. Infections related to cell-based therapies
  • 10e. Infections related to cancer treatment (incl neutropaenia)
  • 10f. Infections related to other forms of immunosuppression (e.g. gastrointestinal, rheumatological, dermatological disease, biologicals) 
  • 11a. General vaccinology (incl in vitro and in vivo studies, safety, regulatory, policy, social aspects)
  • 11b. Antiviral vaccines (excl respiratory and bloodborne viruses)
  • 11c. Antibacterial vaccines
  • 11d. Other preventive modalities (incl new vaccine technologies, antibody-based treatments)
  • 11e. Food & water safety, environmental health, vector epidemiology
  • 11f. Veterinary microbiology and One Health (excl AMR)
  • 11g. Global health & health security (incl policy-making, climate change, biosafety/biosecurity)
  • 11h. Infections in low-resource settings (incl disease burden, health infrastructure, health disparities and vulnerable populations) 
  • 12a. Professional affairs and career development
  • 12b. Publishing, ethics, other academic affairs
  • 12c. Medical education for CM/ID
  • 12d. Diversity and equality
  • 12e. Advocacy and role of patients